title: Evaluation of p53, PCNA, Ki-67, MDM2 and AgNOR in oral peripheral and central giant cell lesions.
abstract: OBJECTIVE
  Peripheral giant cell lesion (PGCL) and central giant cell lesion (CGCL) of the jaws have a distinct clinical behaviour. Whether such biological differences are supported by a distinct pattern of proliferation markers or cell cycle associated proteins expression is not known. Therefore the purpose of the present study was to compare the immunohistochemical expression of p53, MDM2, Ki-67, PCNA and the histochemical expression of argyrophilic nuclear organiser region (AgNOR) on PGCL and CGCL of the jaws.
  
  
  METHODS
  Paraffin wax blocks of 14 cases of PGCL and 12 cases of CGCL were retrieved. A biotin-streptavidin amplified system was used for identification of the antigens. The AgNOR number was also evaluated.
  
  
  RESULTS
  Ki-67 immunoreactivity was greater in the mononuclear cells of PGCL compared to CGCL. PCNA and AgNOR staining were similar in PGCL and CGCL. Prominent MDM2 immunoreactivity was observed in all tissues investigated. By contrast, there was no p53 immunoreactivity.
  
  
  CONCLUSIONS
  Although CGCL present a more aggressive clinical behaviour, it has a decreased proliferative activity compared to PGCL. Finally, p53, MDM2, PCNA, Ki-67 immunohistochemical expression and AgNOR histochemical expression do not reflect their distinct biological behaviour.
authors.affiliation: Department of Oral Surgery and Pathology, School of Dentistry, Minas Gerais Federal University, Minas Gerais, Brazil.
authors.forename: P E
authors.initials: PE
authors.lastname: Souza
authors.forename: R A
authors.initials: RA
authors.lastname: Mesquita
authors.forename: R S
authors.initials: RS
authors.lastname: Gomez
mesh_terms: D015415:Biomarkers / Q000032:analysis; D002455:Cell Division; D002467:Cell Nucleus / Q000648:ultrastructure; D003593:Cytoplasm / Q000648:ultrastructure; D015726:Giant Cells / Q000473:pathology; D005882:Gingival Diseases / Q000473:pathology*; D006101:Granuloma, Giant Cell / Q000473:pathology*; D006801:Humans; D007124:Immunoenzyme Techniques; D007571:Jaw Diseases / Q000473:pathology*; D019394:Ki-67 Antigen / Q000032:analysis*; D007963:Leukocytes, Mononuclear / Q000473:pathology; D009363:Neoplasm Proteins / Q000032:analysis*; D009687:Nuclear Proteins / Q000032:analysis*; D009697:Nucleolus Organizer Region / Q000648:ultrastructure*; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D051736:Proto-Oncogene Proteins c-mdm2; D012834:Silver; D018709:Statistics, Nonparametric; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D015415:Biomarkers; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; D012834:Silver; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2